Page 2 - Patrickj Haley News Today

In this article, we will take a detailed look at Insiders Are Dumping These 10 Healthcare Stocks. For a quick overview of such stocks, read our article Insiders Are Dumping These 5 Healthcare Stocks. Healthcare-focused investors were nervous when 2024 started, since election years usually do not bode well for the healthcare industry amid policy-related uncertainties. But healthcare stocks […]

Trexquant Investment LP lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 94.9% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 451,034 shares of the biotechnology company’s stock after buying an additional 219,567 shares during the period. Trexquant Investment LP owned […]

Trexquant Investment LP grew its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 94.9% during the third quarter, Holdings Channel.com reports. The fund owned 451,034 shares of the biotechnology company’s stock after purchasing an additional 219,567 shares during the quarter. Trexquant Investment LP’s holdings in Exelixis were worth $9,855,000 at the end of the […]

Covestor Ltd increased its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 21.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,996 shares of the biotechnology company’s stock after acquiring an additional 1,238 shares during the period. Covestor Ltd’s holdings in […]

Citigroup Inc. grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 17.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 227,680 shares of the biotechnology company’s stock after purchasing an additional 33,471 shares during the quarter. Citigroup Inc. owned approximately […]

Amalgamated Bank lowered its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 0.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 224,433 shares of the biotechnology company’s stock after selling 2,060 shares during the quarter. Amalgamated Bank owned about 0.07% […]

Exelixis (NASDAQ:EXEL – Get Free Report) had its price target hoisted by equities research analysts at Royal Bank of Canada from $26.00 to $28.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s price target indicates a potential […]

Exelixis (NASDAQ:EXEL – Get Free Report) had its price target upped by equities researchers at Royal Bank of Canada from $26.00 to $28.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s price target points to a potential upside […]

Tealwood Asset Management Inc. trimmed its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 2.4% in the third quarter, Holdings Channel reports. The fund owned 62,063 shares of the biotechnology company’s stock after selling 1,548 shares during the period. Tealwood Asset Management Inc.’s holdings in Exelixis were worth $1,356,000 as of its […]

Banco Santander S.A. bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 70,081 shares of the biotechnology company’s stock, valued at approximately $1,531,000. A number of […]